Publication | Closed Access

A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size

InflammationAutoimmune DiseaseLupusMedicineLupus NephritisImmunologyJak1/2 InhibitionInflammatory Rheumatic DiseasePharmacologyProliferative Lupus NephritisRheumatoid ArthritisJak-stat Signaling PathwayLow Effect Size